Genelux Corporation
NASDAQ:GNLXBiotechnology
+$0.08 today
- Market cap
- $107.66M
- Beta
- 0.55
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.98
Volume 0.80M
Average 0.19M
GNLX Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Genelux CorporationNASDAQ: GNLX
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of $921K (cash outflow) rose 2970.0% year over year, ahead of the +422.0% change in trailing-twelve-month capital expenditures. Sequentially, it rose 111.2% from the prior quarter. Over 3 fiscal years it compounded at +181.9% a year.
Context
- Capital expenditures amounted to 13725.0% of revenue in FY2025, up 8962.5 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +2970.0% holds above the trailing-twelve-month pace of +422.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (1.1M) USD
- Year-over-year change
- -188.2%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.1M) | -188.2% |
| FY2024 | 2024-12-31 | (381K) | +62.8% |
| FY2023 | 2023-12-31 | (1.03M) | -1991.8% |
| FY2022 | 2022-12-31 | (49K) | — |
| FY2021 | 2021-12-31 | 0 | — |
Capital Expenditures vs competitors
How GNLX compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +422.0% is the 2nd highest of 8, against a peer median of +19.8%.
- Capital expenditures amounts to 24862.5% of revenue for GNLX, versus a peer median of 11.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $6.08M USD | — | +88.7% | — | |
| LTM Mar 2026 | $2.23M USD | -44.0% | -1.0% | 3.3% | |
GNLXGenelux Corporation | LTM Mar 2026 | $1.99M USD | +422.0% | +181.9% | 24862.5% |
| LTM Mar 2026 | $1.26M USD | +10391.7% | -23.2% | — | |
| LTM Dec 2025 | CHF 900.16K CHF | +56.3% | -11.5% | 25.2% | |
| LTM Mar 2026 | $623K USD | -8.4% | -68.2% | 2009.7% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $496K USD | +19.8% | +25.1% | — |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $432K USD | +50.0% | -23.9% | — |
| LTM Mar 2026 | $106K USD | — | -53.4% | 11.5% | |
| LTM Mar 2026 | $1.52K USD | -99.5% | +15.4% | 0.3% | |
| LTM Mar 2026 | $4 USD | — | — | — | |
| Peer median (excluding GNLX) | — | +19.8% | -11.5% | 11.5% | |
Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (16.38M) | (5.21M) | (28.3M) | (29.87M) | (32.15M) |
| Depreciation & Amortization | 895K | 968K | 1.02M | 903K | 244K |
| Deferred Income Tax | 348K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.27M | 2.42M | 5.2M | 6.07M | 5.87M |
| Change in Working Capital | 4.08M | (1.69M) | (3.28M) | 751K | (1.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 754K | 2.31M | (2.36M) | 2.16M | (1.21M) |
| Other Working Capital | 3.33M | (4M) | (923K) | (1.41M) | 167K |
| Other Non-Cash Items | 196K | (56K) | 5.08M | 917K | 1.81M |
| Operating Cash Flow | (6.59M) | (3.57M) | (20.28M) | (21.23M) | (25.27M) |
| Capital Expenditures | 0 | (49K) | (1.03M) | (381K) | (1.1M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (13.7M) | (29M) | (18.26M) |
| Sales of Investments | 0 | 0 | 0 | 21.25M | 31.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (49K) | (14.72M) | (8.13M) | 12.14M |
| Debt Repayment | (558K) | 970K | 215K | 0 | 0 |
| Common Stock Issued | 143K | 120K | 39.65M | 27.82M | 9.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 145K | (1.45M) | 4.16M | 688K | 0 |
| Financing Cash Flow | (270K) | (478K) | 44.02M | 28.51M | 9.9M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.86M) | (4.1M) | 9.02M | (853K) | (3.23M) |
| Free Cash Flow | (6.59M) | (3.62M) | (21.3M) | (21.61M) | (26.37M) |
Genelux Corporation
NASDAQ:GNLX
Intrinsic Alpha fair value
Locked
Current Price
$2.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.